All In Biotech

Drug Trial Radar · NCT05047185

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

34

Actual

Start

Apr 19, 2022

Primary completion

Jun 30, 2025

Study completion Jun 30, 2025

Sponsor

Lead sponsor
Pharvaris Netherlands B.V.Industry
Sponsor type
Industry
First posted
Sep 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). The study consists of 2 parts, with patients completing participation in Part 1 prior to initiation of treatment in Part 2. Part 1 of the study has 3 parallel arms and approximately 30 patients will be equally randomized to one of two dose regimens of PHA-022121 or matching placebo. Patients will continue to the single open-label arm in Part 2 of the study after completion of Part 1. The screening period is up to 8 weeks and the treatment periods are 12 weeks (Part 1) and 30 months (Part 2) in duration.

Conditions

  • Hereditary Angioedema
  • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
  • Hereditary Angioedema Types I and II
  • Hereditary Angioedema Attack
  • Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • C1 Esterase Inhibitor Deficiency
  • C1 Inhibitor Deficiency

Interventions

  • Deucrictibant low doseDrug

    Deucrictibant softgel capsules for oral use (PHVS416)

  • Deucrictibant high doseDrug

    Deucrictibant softgel capsules for oral use (PHVS416)

  • PlaceboDrug

    Matching placebo capsules for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Investigator-confirmed Hereditary Angioedema (HAE) Attacks (Expressed as the Normalized Number of Attacks Per Month [4 Weeks] of Exposure) During the Treatment Period in Part 1Time frame: Up to Day 84

Locations

19 sites in 9 countries. Site status is shown where the registry gives one.

  • Study site

    Birmingham, Alabama

  • Study site

    Paradise Valley, Arizona

  • Study site

    St Louis, Missouri

  • Study Site

    Vienna, Austria

  • Study site

    Sofia, Bulgaria

  • Study site

    Ottawa, Ontario, Canada

  • Study site

    Montreal, Quebec, Canada

  • Study site

    Berlin, Germany

  • Study site

    Frankfurt, Germany

  • Study site

    Dublin, Ireland

  • Study site

    Milan, Italy

  • Study site

    Palermo, Italy

  • Study site

    Padua, PD, Italy

  • Study site

    Krakow, Poland

  • Study site

    Brighton, England, United Kingdom

  • Study site

    Bristol, England, United Kingdom

  • Study site

    Cambridge, England, United Kingdom

  • Study site

    London, England, United Kingdom

  • Study site

    Southampton, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.